Anemia and the potential role of erythropoiesis-stimulating agents in heart failure

Current Heart Failure Reports

Volumn 5, Issue 2, 2008, Pages 83-90

  Faraz, Haroon A ^a   Zafar, Syed F ^a   Ghali, Jalal K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 1; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA; ANTIANEMIC AGENT; DRUG DERIVATIVE; IRON DERIVATIVE;

ANEMIA; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PLEIOTROPY; PREVALENCE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; ERYTHROPOIESIS; FEMALE; HOSPITALIZATION; MALE; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIESIS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEART FAILURE, SYSTOLIC; HEMATINICS; HEMOGLOBINS; HUMANS; IRON COMPOUNDS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 58149139548     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-008-0014-0     Document Type: Review

References (62)

1. Rosamond W, Flegal K, Furie K, et al.: Heart disease and stroke statistics-2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e25-e146.
2. Lang CC, Mancini DM: Non-cardiac comorbidities in chronic heart failure. Heart 2007, 93:665-671.
3. Lindenfeld J: Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 2005, 149:391-401.
4. Tang WH, Tong W, Jain A, et al.: Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2008, 51:569-576.
5. Valeur N, Nielsen OW, McMurray JJ, et al.: Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction. Eur J Heart Fail 2006, 8:577-584.
6. Berry C, Norrie J, Hogg K, et al.: The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J 2006, 151:1313-1321.
7. Philipp S, Ollmann H, Schink T, et al.: The impact of anaemia and kidney function in congestive heart failure and preserved systolic function. Nephrol Dial Transplant 2005, 20:915-919.
8. Young JB, Abraham WT, Albert NM, et al.: Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol 2008, 101:223-230.
9. Grigorian Shamagian L, Varela Roman A, Garcia-Acuna JM, et al.: Anaemia is associated with higher mortality among patients with heart failure with preserved systolic function. Heart 2006, 92:780-784.
10. Nair D, Shlipak MG, Angeja B, et al.: Association of anemia with diastolic dysfunction among patients with coronary artery disease in the Heart and Soul Study. Am J Cardiol 2005, 95:332-336.
11. Felker GM, Shaw LK, Stough WG, O'Connor CM: Anemia in patients with heart failure and preserved systolic function. Am Heart J 2006, 151:457-462.
12. O'Meara E, Clayton T, McEntegart MB, et al.: Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2006, 113:986-994.
13. Kosiborod M, Curtis JP, Wang Y, et al.: Anemia and outcomes in patients with heart failure: A study from the National Heart Care Project. Arch Intern Med 2005, 165:2237-2244.
14. Maggioni AP, Opasich C, Anand I, et al.: Anemia in patients with heart failure: Prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail 2005, 11:91-98.
15. Anand IS, Kuskowski MA, Rector TS, et al.: Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: Results from Val-HeFT. Circulation 2005, 112:1121-1127.
16. Ishani A, Weinhandl E, Zhao Z, et al.: Angiotensinconverting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005, 45:391-399.
17. Komajda M, Anker SD, Charlesworth A, et al.: The impact of new onset anaemia on morbidity and mortality in chronic heart failure: Results from COMET. Eur Heart J 2006, 27:1440-1446.
18. Go AS, Yang J, Ackerson LM, et al.: Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006, 113:2713-2723.
19. Latado AL, Passos LC, Darze ES, Lopes AA: Comparison of the effect of anemia on in-hospital mortality in patients with versus without preserved left ventricular ejection fraction. Am J Cardiol 2006, 98:1631-1634.
20. Varadarajan P, Gandhi S, Sharma S, et al.: Prognostic significance of hemoglobin level in patients with congestive heart failure and normal ejection fraction. Clin Cardiol 2006, 29:444-449.
21. Tada T, Shiba N, Watanabe J, et al.: Prognostic value of anemia in predicting sudden death of patients with diastolic heart failure. Int J Cardiol 2007 Jul 20 (Epub ahead of print).
22. Schou M, Gustafsson F, Kistorp CN, et al.: Prognostic usefulness of anemia and N-terminal pro-brain natriuretic peptide in outpatients with systolic heart failure. Am J Cardiol 2007, 100:1571-1576.
23. Desai AS, Bibbins-Domingo K, Shlipak MG, et al.: Association between anaemia and N-terminal pro-B-type natriuretic peptide (NT-proBNP): findings from the Heart and Soul Study. Eur J Heart Fail 2007, 9:886-891.
24. Baggish AL, van Kimmenade R, Bayes-Genis A, et al.: Hemoglobin and N-terminal pro-brain natriuretic peptide: Independent and synergistic predictors of mortality in patients with acute heart failure: Results from the International Collaborative of NT-proBNP (ICON) Study. Clin Chim Acta 2007, 381:145-150.
25. Fukuta H, Ohte N, Mukai S, et al.: Anemia is an independent predictor for elevated plasma levels of natriuretic peptides in patients undergoing cardiac catheterization for coronary artery disease. Circ J 2008, 72:212-217.
26. Hogenhuis J, Voors AA, Jaarsma T, et al.: Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail 2007, 9:787-794.
27. Ralli S, Horwich TB, Fonarow GC: Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J 2005, 150:1220-1227.
28. van der Putten K, Braam B, Jie KE, Gaillard CA: Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 2008, 4:47-57.
29. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
30. Theurl I, Mattle V, Seifert M, et al.: Dysregulated monocyte iron homeostasis and erythropoetin formation in patients with anemia of chronic disease. Blood 2006, 107:4142-4148.
31. Wrighting DM, Andrews NC: Interleukin-6 induces hepcidin expression through STAT3. Blood 2006, 108:3204-3209.
32. Opasich C, Cazzola M, Scelsi L, et al.: Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005, 26:2232-2237.
33. Westenbrink BD, Visser FW, Voors AA, et al.: Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007, 28:166-171.
34. Nanas JN, Matsouka C, Karageorgopoulos D, et al.: Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006, 48:2485-2489.
35. Terrovitis JV, Anastasiou-Nana MI, Alexopoulos GP, et al.: Prevalence and prognostic significance of anemia in patients with congestive heart failure treated with standard vs high doses of enalapril. J Heart Lung Transplant 2006, 25:333-338.
36. van der Meer P, Lipsic E, Westenbrink BD, et al.: Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysylproline partially explain the occurrence of anemia in heart failure. Circulation 2005, 112:1743-1747.
37. Tang YD, Katz SD: Anemia inPchronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006, 113:2454-2461.
38. Damman K, Navis G, Voors AA, et al.: Worsening renal function and prognosis in heart failure: Systematic review and meta-analysis. J Card Fail 2007, 13:599-608.
39. Bongartz LG, Cramer MJ, Doevendans PA, et al.: The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005, 26:11-17.
40. Palazzuoli A, GallotAa M, Iovine F, et al.: Anaemia in heart failure: a common interaction with renal insufficiency called the cardio-renal anaemia syndrome. Int J Clin Pract 2008, 62:281-286.
41. Jie KE, Verhaar MC, Cramer MJ, et al.: Erythropoietin and the cardiorenal syndrome: Cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 2006, 291:F932-F944.
42. Depping R, Kawakami K, Ocker H, et al.: Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg 2005, 130:877-878.
43. Westenbrink BD, Lipsic E, van der Meer P, et al.: Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007, 28:2018-2027.
44. Lipsic E, Westenbrink BD, van der Meer P, et al.: Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008, 10:22-29.
45. Nishiya D, Omura T, Shimada K, et al.: Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 2006, 101:31-39.
46. Li Y, Takemura G, Okada H, et al.: Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006, 71:684-694.
47. Lipsic E, Schoemaker RG, van der Meer P, et al.: Protective effects of erythropoietin in cardiac ischemia: From bench to bedside. J Am Coll Cardiol 2006, 48:2161-2167.
48. Asaumi Y, Kagaya Y, Takeda M, et al.: Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007, 115:2022-2032.
49. Namiuchi S, Kagaya Y, Ohta J, et al.: High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005, 45:1406-1412.
50. Jelkmann W: Erythropoietin after a cenYury of research: younger than ever. Eur J Haematol 2007, 78:183-205.
51. Palazzuoli A, Silverberg D, Iovine F, et al.: Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006, 152:1096.e9-1096.e15.
52. Palazzuoli A, Silverberg DS, Iovine F, et al.: Effects of betaerythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007, 154:645.e9-645.e15.
53. Zilberman M, Silverberg DS, Bits I, et al.: Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure. Am Heart J 2007, 154:870-876.
54. Kourea K, Parissis JT, Farmakis D, et al.: Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerosis 2007 Nov 6 (Epub ahead of print).
55. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al.: Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007, 28:2208-2216.
56. Ponikowski P, Anker SD, Szachniewicz J, et al.: Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007, 49:753-762.
57. Ghali JK, Anand IS, Abraham WT, et al.: Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008, 117:526-535.
58. Young JB, Anand IS, Diaz R, et al.: Reduction of Events With Darbepoetin Alfa in Heart Failure (RED-HF) trial [abstract]. J Card Fail 2006, 12(Suppl 1):S77.
59. Okonko DO, Grzeslo A, Witkowski T, et al.: Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptAmatic chronic heart failure and iron deficiency: FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008, 51:103-112.
60. Bolger AP, Bartlett FR, Penston HS, et al.: Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006, 48:1225-1227.
61. Toblli JE, Lombrana A, Duarte P, Di Gennaro F: Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007, 50:1657-1665.
62. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, et al.: Rationale and design of the IRON-HF study: A randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Card Fail 2007, 13:14-17.